Furthermore, research has demonstrated that Falcarindiol (FAD) enhances HCC sensitivity to the chemotherapeutic agent cisplatin (DDP) by inhibiting the STAT3/PTTG1 signaling pathway [48]. The gene discussed is STAT3; the disease is hepatocellular carcinoma.